Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19-and CYP3A4/5-phenotyped patients

Steady state plasma concentrations of the (L)- and (D)-enantiomers of trimi pramine (TRI), desmethyltrimipramine (DTRI), 2-hydroxytrimipramine (TRIOH) and 2-hydroxydesmethyl-trimipramine (DTRIOH) were measured in 27 patients r eceiving between 300 and 400 mg/day racemic TRI. The patients were phenotyp ed with dextromethorphan and mephenytoin, and the 8-hour urinary ratios of dextromethorphan/dextrorphan, dextromethorphan/3-methoxymorphinan, and (S)- mephenytoin/(R)mephenytoin were used as markers of cytochrome P-450IID6 (CY P2D6), CYP3A4/5 and CYP2C19 activities, respectively. One patient was a CYP 2D6 and one was a CYP2C19 poor metabolizer. A stereoselectivity in the meta bolism of TRI has been found, with a preferential N-demethylation of (D)-TR I and a preferential hydroxylation of (L)-TRI. CYP2D6 appears to be involve d in the 2-hydroxylation of (L)-TRI, (L)DTRI and (D)-DTRI, but not of (D)-T RI, as significant correlations were measured between the dextromethorphan/ dextrorphan ratios and the (L)-TRI(L)-TRIOH (r = 0.45, p = 0.019), the (L)- DTRI/(L)-DTRIOH (r = 0.47, p = 0.014), and the (D)-DTRI/(D)-DTRIOH (r = 0.5 1, p = 0.006), but not with the (D)-TRI(D)-TRIOH ratios (r = 0.29, NS). CYP 2C19, but not CYP2D6, appears to be involved in the demethylation pathway, with a stereoselectivity toward the (D)-enantiomer of TRI, as a significant positive correlation was calculated between the mephenytoin (S)/(R) ratios and the concentrations to dose-to-weight ratios of (D)-TRT (r = 0.69, p = 0.00006). CYP3A4/5 appears to be involved in the metabolism of (L)-TRT to a presently not determined metabolite. The CYP2D6 poor metabolizer had the h ighest (L)DTRI and (D)-DTRI concentrations to dose-to-weight ratios, and th e CYP2C19 poor metabolizer had the highest (L)-TRI and (D)-TRI concentratio ns to dose-to-weight ratios of the group.